The last five years have seen an unparalleled development of therapies targeting severe and/or refractory forms of myasthenia gravis (MG). US clinicians shared their experiences as prescribers at two seminars organised by the federal MGNet network.
- This concerned in particular innovative complement-targeted drugs or other Fc receptor inhibitor drugs.
- The question of the effectiveness and cost-benefit ratio of these new therapies remains, however, in view of their frequently exorbitant price.
- Other issues such as the need for registries of treated patients and more sensitive biomarkers were also discussed.
Although a consensus on the use of these new drugs is difficult to reach, the sharing of real-life practices is always useful.